Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Share-based Compensation: 2020-2024

Historic Share-based Compensation for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $2.9 million.

  • SAB Biotherapeutics' Share-based Compensation fell 23.65% to $800,764 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 36.30%. This contributed to the annual value of $2.9 million for FY2024, which is 24.21% down from last year.
  • According to the latest figures from FY2024, SAB Biotherapeutics' Share-based Compensation is $2.9 million, which was down 24.21% from $3.9 million recorded in FY2023.
  • SAB Biotherapeutics' Share-based Compensation's 5-year high stood at $3.9 million during FY2023, with a 5-year trough of $1.3 million in FY2020.
  • For the 3-year period, SAB Biotherapeutics' Share-based Compensation averaged around $3.2 million, with its median value being $2.9 million (2024).
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 78.68% in 2021, then fell by 24.21% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' Share-based Compensation (Yearly) stood at $1.3 million in 2020, then skyrocketed by 78.68% to $2.3 million in 2021, then climbed by 15.53% to $2.7 million in 2022, then surged by 45.15% to $3.9 million in 2023, then fell by 24.21% to $2.9 million in 2024.